00:05This is Missy Green with Nutrition Insight at Vita Foods 2023 and I'm here with Chin at Morinaga Milk.

00:12So why is it so important to use strains from human origin, probiotic strains from human origin?

00:19So we have been conducting the studies on human residential bacteria for over half of a century.

00:27More than 50 years.

00:29At first we wouldn't actually know what is so important with the human strain.

00:34We were just having a belief that, you know, it is better to give baby the strains that were actually originated from human body.

00:42So we have always focused on the strains that were actually originated from humans.

00:48It was just a decade ago that we started to compare.

00:52The strains that were isolated from humans and the strains that were isolated from animals.

00:58And the first study that we conducted was actually just by chance.

01:02We, we, we didn't plan to actually conduct such a study.

01:05It was just, you know, a curiosity from our scientists who, you know, have a wife just give birth to a baby and the, the mother actually has a lot of breast milk left.

01:17And he just come up with a very, nice idea, you know, why not we grow different types of vivid bacteria in breast milk to see would it be having any difference, you know, comparing different strains.

01:32So he just grow, you know, one by one in different, one strains by one strains in this breast milk and to see what is the result.

01:41And we were also surprised with the result that only the HIV strains, that those that originated from humans can survive.

01:50And those that are not, those that are isolated from animal sources or fermented or dairy products cannot survive.

01:58So that's where we started to believe that, you know, HIV strains would actually have superiority in terms of physiological function.

02:08And that's the start of our journey on HIV studies.

02:13From there, we started to learn and also read some studies about, you know, HMO utilization.

02:20And end up a lot of other researchers have also doing the same research saying that only certain kind of the feed the bacterial strains can utilize HMOs because they have the genetic elements to encode the enzymes that can utilize, that can cut the human milk olicosac rites into a smaller, immuno sorry, smaller, monosacrites and then the, the infant host can utilize them.

02:51So, it was just, you know, a coincidence that we actually started this research and we found it is really interesting.

02:58So we continue to research on it.

03:01First, we conduct studies on, you know, er identifying HMO utilizing with the bacteria.

03:07And subsequently, we also identifying what are the beneficial metabolites produced by this group of bacteria that can utilize HMO and through our studies, we found that those that can utilizing HMOs are B.

03:22Longer strain, B.

03:23Brave strain, B.

03:25Infant strains.

03:26And these strains, they have features such as, producing folate, which is vitamin B9, and, and on the other hand, they also produce tryptophan derivatives in aromatic lactic acid such as indotri lactic acid.

03:43And we were among the very first group of researchers that actually put a focus on ILA, which is, industry lactic acids Research.

03:53We were among the first to actually wanted to know what is the functions of ILA.

03:59And, me myself actually was a scientist at that time.

04:03I also conducted a study to, to find out the benefits.

04:08Visal functions of IOA.

04:10And one of the potential effects of IOA is to promote neuronal differentiation, which we could think that it could be a benefit for infants in brain development in early life.

04:22And at the same time, when I remember when I've, conducted the study, I tried to search for the studies from other research groups.

04:30They were actually very limited, sources, very limited.

04:34With references at that time.

04:37But a few years later, just 2 years later, this IOA become a very hot metabolite in the field of HMO research.

04:46Because and many other group of researchers also found that those that are able to utilize in HMO, those with the bacteria that are able to utilize HMO, they also produce high levels of IRA.

05:01And they try to understand the benefits, the role of IOA.

05:05And they found that IOA is actually related to immunomodulation and also immune, development in infants.

05:14And that is kind of like back with our science and also the signs from other research team give us more confident that HIV strains are the one that is more suitable for human health.

05:25And of course, for Morinaga, we will continue our study.

05:30To find out the unique metabolite produced by HRB and also the unique physiological functions that HRB could have.

05:37And we will continue to provide this as a solution to many different manufacturers.

05:45So, will IOA only be produced if these bacteria are fed HMOs or will they also produce IOA if they're also fed like gas or.

05:56So that's a very nice question.

05:58So, it could be, you know, depending on the culture condition and also the, the, the, the combinations of the carbohydrate sauce.

06:11In the media.

06:13So, we, we, we, we, we can also see the similar results if we actually grow, these strains in goals of false that they could also produce IRA, but the level could be actually could be lesser, as compared to HMO.

06:32But if you were to, you know, play around with, the combinations of, for example, goals plus forces to make it more.

06:41Suitable for the growth of the beef bacteria, then the amount of the metabolite would be higher.

06:49Yeah.

06:49So there's a lot of work that, you know, manufacturer can, can actually do to try to come up with a good formulation that is suitable, not only, you know, for the infant health, but also, you know, focus on the probiotics itself, how it could actually help with the growth of the probiotics.

07:10Yeah.

07:11OK, thank you.

07:12Thank you.